Benjamin Ortiz Selected Research

Omalizumab (Xolair)

1/2021	Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations.
1/2020	Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity.
1/2020	Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.
1/2020	Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population.
10/2019	Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
1/2019	Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.
1/2019	Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study.
1/2019	Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018.
7/2018	Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States.
5/2018	Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Benjamin Ortiz Research Topics

Disease

36	Asthma (Bronchial Asthma) 01/2023 - 01/2017
8	Inflammation (Inflammations) 01/2023 - 01/2021
7	Rhinosinusitis 01/2023 - 01/2021
6	Nasal Polyps (Nasal Polyp) 01/2023 - 01/2021
6	Urticaria (Hives) 01/2019 - 01/2017
5	Chronic Urticaria 01/2019 - 01/2017
2	Atopic Dermatitis (Atopic Eczema) 10/2022 - 01/2022
1	Obstructive Lung Diseases (Obstructive Lung Disease) 01/2023
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2023
1	Eosinophilic Esophagitis 10/2022
1	Eosinophilia 10/2022
1	Churg-Strauss Syndrome (Allergic Angiitis) 10/2022
1	Pruritus (Itching) 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022
1	Infections 01/2022
1	Eczema 01/2022
1	Anosmia 01/2022
1	Hypersensitivity (Allergy) 10/2019

Drug/Important Bio-Agent (IBA)

20	Omalizumab (Xolair)FDA Link 01/2021 - 01/2017
18	dupilumabIBA 01/2023 - 01/2021
15	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 05/2017
6	Bronchodilator Agents (Bronchodilators)IBA 01/2023 - 01/2022
5	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2023 - 10/2019
4	Immunoglobulin E (IgE)IBA 01/2023 - 01/2018
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 10/2019
3	Interleukin-13IBA 01/2023 - 01/2021
3	Monoclonal AntibodiesIBA 01/2022 - 01/2021
3	anti-IgE antibodiesIBA 01/2020 - 05/2017
3	Histamine Antagonists (Antihistamines)IBA 01/2019 - 12/2017
2	InterleukinsIBA 10/2022 - 01/2022
2	Interleukin-4 (Interleukin 4)IBA 01/2022 - 01/2021
2	3- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)IBA 01/2019 - 03/2018
1	CytokinesIBA 01/2023
1	SteroidsIBA 01/2022
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2022
1	Mometasone Furoate (Nasonex)FDA LinkGeneric 01/2022
1	Nasal SpraysIBA 01/2022
1	Indicators and Reagents (Reagents)IBA 03/2018
1	LeukotrienesIBA 01/2018
1	Adrenergic Agonists (Adrenergic Receptor Agonist)IBA 01/2018
1	AllergensIBA 05/2017
1	HCEIBA 01/2017
1	Prescription DrugsIBA 01/2017
1	insulin receptor-related receptor (IRR)IBA 01/2017

Therapy/Procedure

5	Therapeutics 01/2020 - 01/2018